XML 41 R29.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)
 3 Months Ended
Jan. 22, 2024
Aug. 15, 2023
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Summary of Significant Accounting Policies          
Cash and cash equivalents     $ 7,976,106   $ 14,849,057
Accumulated deficit     156,413,660   145,491,559
Net Income (Loss)     (10,922,101) $ (5,739,366)  
Cash used in operations     (9,891,747) (6,958,708)  
Treasury bills     2,039,357   5,450,118
Cash, uninsured amount     7,301,681   14,243,870
Deferred clinical supply costs     846,301   4,256,793
Write-down of inventories to net realizable value     $ 198,034 $ 0  
License | Formosa Pharmaceuticals Inc          
Summary of Significant Accounting Policies          
Percentage of product approved by FDA   0.05%      
Upfront payment paid in cash   $ 1,000,000.0      
Issuance of common stock as consideration for licensing agreement (in shares)   487,805      
Issuance of common stock as consideration for licensing agreement   $ 1,000,000.0      
Legal expenses capitalized   122,945      
Maximum amount payable upon achievement of certain development milestones   4,000,000.0      
Maximum amount payable upon achievement of certain sales milestones   80,000,000.0      
Upfront payment   $ 2,000,000.0      
Clinical Supply Arrangements          
Summary of Significant Accounting Policies          
Clinical trials, percentage of additional mark-up on cost     10.00%    
Deferred clinical supply costs     $ 800,000   $ 4,300,000
Bausch License Agreement | License          
Summary of Significant Accounting Policies          
Issue of common stock $ 2,000,000.0        
Upfront payment received $ 3,000,000.0